Connect with us

Health

Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian

Australian company applies for permission to conduct trial of men and women aged 18 to 55

Published

on

ADVERTISEMENT

Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Evolutionary biologists discover mechanism that enables lizards to breathe underwater – Newswise
Weird dreams train us for the unexpected, says new theory – The Guardian